Tags

Type your tag names separated by a space and hit enter

The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
Bone. 2005 Feb; 36(2):358-64.BONE

Abstract

Osteoporosis has become an important health problem in postmenopausal Asian populations as the prevalence of hip and vertebral fractures in some Asian countries has risen to approach that of Caucasian populations. Risedronate, a pyridinyl-bisphosphonate agent, is a potent inhibitor of bone resorption. Risedronate increases bone mineral density (BMD), reduces markers of bone turnover, and reduces the risk of fractures in Caucasian postmenopausal women. To determine the efficacy and tolerability of risedronate in Chinese, a multicenter, randomized, double blind, placebo controlled study was performed in Hong Kong. Sixty-five (65) postmenopausal osteoporotic Southern Chinese women, aged 67+/-6 years, were randomly assigned to receive either risedronate 5 mg daily (n=31) or placebo (n=34) for 12 months. All women received calcium carbonate 500 mg daily and vitamin D 400 IU daily. Mean baseline BMD T-score at the spine and total hip was -3.4 and -2.6, respectively. A significant increase in spine BMD was already evident at month 3 of risedronate treatment (P<0.001). Risedronate significantly increased BMD and reduced bone turnover markers as compared with placebo. The risedronate group had significant increase in BMD at 12 months at both the spine and hip when compared with the placebo group (L1-4 6.6% vs. 0.4%, P<0.001; total hip 2.7% vs. 0.3, P<0.0001; femoral neck 1.8% vs. 1.1%, P<0.02; trochanter 4% vs. 1.1%, P<0.0001, respectively). Significant changes in urine N-telopeptide (NTx) and serum osteocalcin were evident as early as 1 and 3 months, respectively, with risedronate treatment. No significant changes were seen in both BMD and bone markers in the placebo group. Risedronate was well tolerated without major adverse effects. We conclude that risedronate is an effective and well-tolerated agent for the treatment of postmenopausal osteoporosis in Asian population.

Authors+Show Affiliations

Department of Medicine and Geriatrics, Ruttonjee Hospital, Hong Kong, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15780963

Citation

Leung, Jenny Y Y., et al. "The Efficacy and Tolerability of Risedronate On Bone Mineral Density and Bone Turnover Markers in Osteoporotic Chinese Women: a Randomized Placebo-controlled Study." Bone, vol. 36, no. 2, 2005, pp. 358-64.
Leung JY, Ho AY, Ip TP, et al. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. Bone. 2005;36(2):358-64.
Leung, J. Y., Ho, A. Y., Ip, T. P., Lee, G., & Kung, A. W. (2005). The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. Bone, 36(2), 358-64.
Leung JY, et al. The Efficacy and Tolerability of Risedronate On Bone Mineral Density and Bone Turnover Markers in Osteoporotic Chinese Women: a Randomized Placebo-controlled Study. Bone. 2005;36(2):358-64. PubMed PMID: 15780963.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. AU - Leung,Jenny Y Y, AU - Ho,Andrew Y Y, AU - Ip,T P, AU - Lee,Gavin, AU - Kung,Annie W C, PY - 2004/08/11/received PY - 2004/09/23/revised PY - 2004/10/26/accepted PY - 2005/3/23/pubmed PY - 2005/7/29/medline PY - 2005/3/23/entrez SP - 358 EP - 64 JF - Bone JO - Bone VL - 36 IS - 2 N2 - Osteoporosis has become an important health problem in postmenopausal Asian populations as the prevalence of hip and vertebral fractures in some Asian countries has risen to approach that of Caucasian populations. Risedronate, a pyridinyl-bisphosphonate agent, is a potent inhibitor of bone resorption. Risedronate increases bone mineral density (BMD), reduces markers of bone turnover, and reduces the risk of fractures in Caucasian postmenopausal women. To determine the efficacy and tolerability of risedronate in Chinese, a multicenter, randomized, double blind, placebo controlled study was performed in Hong Kong. Sixty-five (65) postmenopausal osteoporotic Southern Chinese women, aged 67+/-6 years, were randomly assigned to receive either risedronate 5 mg daily (n=31) or placebo (n=34) for 12 months. All women received calcium carbonate 500 mg daily and vitamin D 400 IU daily. Mean baseline BMD T-score at the spine and total hip was -3.4 and -2.6, respectively. A significant increase in spine BMD was already evident at month 3 of risedronate treatment (P<0.001). Risedronate significantly increased BMD and reduced bone turnover markers as compared with placebo. The risedronate group had significant increase in BMD at 12 months at both the spine and hip when compared with the placebo group (L1-4 6.6% vs. 0.4%, P<0.001; total hip 2.7% vs. 0.3, P<0.0001; femoral neck 1.8% vs. 1.1%, P<0.02; trochanter 4% vs. 1.1%, P<0.0001, respectively). Significant changes in urine N-telopeptide (NTx) and serum osteocalcin were evident as early as 1 and 3 months, respectively, with risedronate treatment. No significant changes were seen in both BMD and bone markers in the placebo group. Risedronate was well tolerated without major adverse effects. We conclude that risedronate is an effective and well-tolerated agent for the treatment of postmenopausal osteoporosis in Asian population. SN - 8756-3282 UR - https://www.unboundmedicine.com/medline/citation/15780963/The_efficacy_and_tolerability_of_risedronate_on_bone_mineral_density_and_bone_turnover_markers_in_osteoporotic_Chinese_women:_a_randomized_placebo_controlled_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S8756-3282(04)00429-6 DB - PRIME DP - Unbound Medicine ER -